Show simple item record

dc.contributor.authorCallender, Lauren A.
dc.contributor.authorCurran, Michelle
dc.contributor.authorBates, Stephanie M.
dc.contributor.authorMairesse, Maelle
dc.contributor.authorWeigandt, Julia
dc.contributor.authorBetts, Catherine J.
dc.date.accessioned2020-08-26T16:19:56Z
dc.date.available2020-08-26T16:19:56Z
dc.date.issued2020-08-11
dc.date.submitted2020-06-03
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/309638
dc.description.abstractEvidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.
dc.languageen
dc.publisherFrontiers Media S.A.
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectImmunology
dc.subjectimmunology and infectious diseases
dc.subjectCOVID-19
dc.subjectinflammatory diseases
dc.subjectvirus immunity
dc.subjectSARS-CoV-2
dc.subjectinflammation
dc.subjectrespiratory disease
dc.subjectcomorbidities
dc.titleThe Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
dc.typeArticle
dc.date.updated2020-08-26T16:19:56Z
prism.publicationNameFrontiers in Immunology
prism.volume11
dc.identifier.doi10.17863/CAM.56733
dcterms.dateAccepted2020-07-23
rioxxterms.versionofrecord10.3389/fimmu.2020.01991
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.identifier.eissn1664-3224


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)